A COVID-19 vaccine developed by India’s Bharat Biotech is safe and has shown high levels of antibody response in a mid-stage trial, but follow-on studies are needed to evaluate the shot for children and older people, a peer-reviewed study showed.
Read more
Bharat Biotech’s vaccine showed 81% efficacy in preventing symptomatic COVID-19 in an interim analysis of a late-stage trial in India, it said on Wednesday, a major boost for the shot shunned by some due to a lack of such data.
Read more
Brazil’s Health Ministry on Thursday signed a contract to purchase 20 million doses of Covaxin, the COVID-19 vaccine made by India’s Bharat Biotech, for delivery between March and May.
Read more
A man rides his motorbike past a parked bus of India's biotechnology company Bharat Biotech outside its office in Hyderabad, India July 3, 2020. REUTERS/Stringer/Files
Read more
India’s Bharat Biotech submitted on Thursday an application for the emergency use of its COVID-19 vaccines in the Philippines, Food and Drug Administration chief Rolando Enrique Domingo said.
Read more
